MAPS Statement on Bipartisan Congressional Letter to FDA
Washington DC — Reps. Jack Bergman (R-MI) and Lou Correa (D-CA), co-chairs of the Congressional Psychedelics Advancing Therapies Caucus, led a bipartisan group of 30 members of Congress in a letter to Food and Drug Administration (FDA) Commissioner Martin A. Makary, urging the agency to advance evaluation of psychedelic-assisted therapies. The letter asks FDA to… Continue reading MAPS Statement on Bipartisan Congressional Letter to FDA
External link. We are not responsible for the content.
Read more ↗More From MAPS
University of Miami’s Gift of 1994 Ibogaine IND to HHS Sets a Standard for Open Science
Washington, D.C., August 25, 2026 — The Multidisciplinary Association for Psychedelic Studies (MAPS)has welcomed the ...
MAPS Responds to Report of Progress for MDMA-assisted therapy for PTSD with FDA
August 10, 2026 — The non-profit Multidisciplinary Association for Psychedelic Studies (MAPS) today responded to an A...
MAPS Announces Agreement with UAB
MAPS can now share we have finalized a clinical trial agreement with the University of Alabama, Birmingham, making UA...
Latest News
Why Most Drugs Fail, and Why Virtual Tissue Models Beat Virtual Cell Models
Welcome back to Business Trip by PsyMed Ventures, a podcast exploring the future of mental health & wellness!
Ibogaine’s Momentum Is Real. So Is the Safety Gap Nobody’s Solving.
Recent reporting, has documented a string of serious adverse events at overseas psychedelic clinics such as cardiac d...
Was Carlos Castaneda Among the First Psychedelic Grifters?
Author Carlos Castaneda built a fortune on a fabricated Indigenous lineage. A new biography shows how his blueprint s...
Who Gets to Heal?
A donor gift with no diagnosis requirement forced a debate inside Thank You Life. Its executive director asks whether...
Weekly Psychedelic Policy Briefing: August 23, 2026
Oregon's psilocybin program posted its first real-world outcome data this week, just as regulators move on fee increa...
What’s stopping psychedelic therapy in China? 5 Questions with medical ethicist Jennifer Docherty
Docherty discusses her interviews about psychedelic end-of-life care with clinicians in Hong Kong.